LU92336I2 - Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA) - Google Patents

Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)

Info

Publication number
LU92336I2
LU92336I2 LU92336C LU92336C LU92336I2 LU 92336 I2 LU92336 I2 LU 92336I2 LU 92336 C LU92336 C LU 92336C LU 92336 C LU92336 C LU 92336C LU 92336 I2 LU92336 I2 LU 92336I2
Authority
LU
Luxembourg
Prior art keywords
kadcyla
pharmaceutically acceptable
acceptable derivatives
trastuzumab emtansine
emtansine
Prior art date
Application number
LU92336C
Other languages
English (en)
Other versions
LU92336I9 (fr
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34467962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92336(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of LU92336I2 publication Critical patent/LU92336I2/fr
Publication of LU92336I9 publication Critical patent/LU92336I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
LU92336C 2003-10-10 2013-12-16 Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA) LU92336I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50990103P 2003-10-10 2003-10-10
US10/960,602 US8088387B2 (en) 2003-10-10 2004-10-08 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PCT/US2004/030917 WO2005037992A2 (fr) 2003-10-10 2004-10-12 Procede de ciblage de populations cellulaires specifiques a l'aide de conjugues formes d'un agent de liaison cellulaire et de maytansinoides, lies par l'intermediaire d'un lieur non clivable, lesdits conjugues et leurs procedes de preparation

Publications (2)

Publication Number Publication Date
LU92336I2 true LU92336I2 (fr) 2014-02-17
LU92336I9 LU92336I9 (fr) 2019-01-16

Family

ID=34467962

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92336C LU92336I2 (fr) 2003-10-10 2013-12-16 Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)

Country Status (26)

Country Link
US (10) US8088387B2 (fr)
EP (4) EP1689846B1 (fr)
JP (10) JP2007520450A (fr)
KR (4) KR101573124B1 (fr)
CN (3) CN103223174A (fr)
AU (2) AU2004282491C1 (fr)
BE (1) BE2013C075I2 (fr)
BR (1) BRPI0415448A8 (fr)
CA (3) CA2542128C (fr)
CY (2) CY1113984T1 (fr)
DK (1) DK1689846T3 (fr)
EA (1) EA010508B1 (fr)
EC (1) ECSP066461A (fr)
ES (1) ES2404304T3 (fr)
FR (1) FR13C0068I2 (fr)
HK (1) HK1244452A1 (fr)
HR (1) HRP20130412T1 (fr)
HU (1) HUS1300075I1 (fr)
IL (4) IL173625A (fr)
LU (1) LU92336I2 (fr)
NO (2) NO337458B1 (fr)
NZ (2) NZ545195A (fr)
PL (1) PL1689846T3 (fr)
PT (1) PT1689846E (fr)
SI (1) SI1689846T1 (fr)
WO (1) WO2005037992A2 (fr)

Families Citing this family (338)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385528C (fr) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
NZ536475A (en) * 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1718667B1 (fr) * 2004-02-23 2013-01-09 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
JP5165387B2 (ja) 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
EP3539572A1 (fr) 2005-08-24 2019-09-18 ImmunoGen, Inc. Procédé de préparation de conjugués d'anticorps de maytansinoïde
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007100385A2 (fr) * 2005-10-31 2007-09-07 Genentech, Inc. Conjugués anticorps-médicaments à base de depsipeptide macrocyclique et méthodes associées
CN103193885B (zh) 2006-01-20 2015-05-13 健泰科生物技术公司 抗ephrinb2抗体及其使用方法
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
WO2007140371A2 (fr) 2006-05-30 2007-12-06 Genentech, Inc. Anticorps et immuno-conjugués, et leurs utilisations
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2126127B1 (fr) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Utilisation d'anticorps anti-egfr dans le traitement de maladie mediee par des mutants de recepteur du facteur de croissance epidermique (egfr)
CA2680854C (fr) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Procede de traitement utilisant des anticorps d'egfr et des inhibiteurs de src, et formulations en rapport
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) * 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2009134870A1 (fr) * 2008-04-30 2009-11-05 Immunogen, Inc. Conjugués de médicament d’agent de liaison cellulaire puissant
RU2487877C2 (ru) * 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
EP2281006B1 (fr) * 2008-04-30 2017-08-02 Immunogen, Inc. Agents de réticulation et leurs utilisations
US20100092495A1 (en) * 2008-04-30 2010-04-15 Immunogen Inc. Potent cell-binding agent drug conjugates
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
HRP20150965T1 (hr) * 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
CA2757382A1 (fr) 2009-04-01 2010-10-21 Kristi Elkins Anticorps anti-fcrh5 et immunoconjugues
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
JP5863640B2 (ja) 2009-04-29 2016-02-16 バイオ−ラッド ラボラトリーズ インコーポレーティッド 免疫複合体の精製
JP2012526839A (ja) 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
EP2437790B1 (fr) 2009-06-03 2019-02-20 Immunogen, Inc. Procédés de conjugaison
PT2437785E (pt) 2009-06-04 2015-04-20 Novartis Ag Método de identificação de sítios para conjugação de igg
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
KR101881714B1 (ko) * 2009-10-26 2018-07-24 네스텍 소시에테아노님 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
NZ600826A (en) 2009-12-23 2014-09-26 Genentech Inc Anti-bv8 antibodies and uses thereof
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130332A1 (fr) 2010-04-12 2011-10-20 Academia Sinica Puces au glycane pour la recherche par criblage haut débit de virus
CA2796633C (fr) 2010-04-23 2020-10-27 Genentech, Inc. Production de proteines heteromultimeres
BR112012029866A2 (pt) 2010-06-03 2017-03-07 Genentech Inc método para a determinação da presença de uma proteína steap-1
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
WO2012019024A2 (fr) 2010-08-04 2012-02-09 Immunogen, Inc. Molécules se liant à her3 et leurs immunoconjugués
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
KR20140008308A (ko) 2010-10-29 2014-01-21 이뮤노젠 아이엔씨 신규한 egfr-결합 분자 및 이의 면역컨쥬게이트
CN103328505B (zh) * 2010-10-29 2015-12-02 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012106587A1 (fr) 2011-02-04 2012-08-09 Genentech, Inc. Variantes génétiques de fc et leurs procédés de production
KR20140010076A (ko) 2011-02-15 2014-01-23 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
WO2012135517A2 (fr) 2011-03-29 2012-10-04 Immunogen, Inc. Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
CN103619357A (zh) * 2011-03-29 2014-03-05 伊缪诺金公司 用于制造具有改善的同质性的缀合物的方法
PL2694106T3 (pl) 2011-04-01 2018-06-29 Immunogen, Inc. Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1
CN105999293B (zh) 2011-04-01 2019-07-23 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
US20140161827A1 (en) 2011-05-09 2014-06-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
EP2714738B1 (fr) 2011-05-24 2018-10-10 Zyngenia, Inc. Complexes plurispécifiques multivalents et monovalents, et leurs utilisations
CA2837840C (fr) 2011-06-10 2020-08-04 Mersana Therapeutics, Inc. Conjugues de medicament-proteine-polymere
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
MX350954B (es) 2011-06-21 2017-09-26 Immunogen Inc Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos.
EP2736928B1 (fr) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Proteines "sur"-liantes dirigees contre erbb3
ES2806146T3 (es) 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L
US9364551B2 (en) 2011-09-29 2016-06-14 Virginia Commonwealth University Light-enabled drug delivery
PH12014500925A1 (en) 2011-10-28 2014-06-09 Genentech Inc Therapeutic combinations and methods of treating melanoma
HK1202252A1 (en) 2011-11-16 2015-09-25 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
SG11201402887SA (en) 2011-12-08 2014-07-30 Biotest Ag Uses of immunoconjugates targeting cd138
EP2793940B1 (fr) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Protéines substitutives de liaison
AU2012356894B2 (en) 2011-12-23 2018-01-18 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
HK1204445A1 (en) 2012-01-20 2015-11-20 Sea Lane Biotechnologies, Llc Surrobody cojugates
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
CA2869704A1 (fr) * 2012-04-04 2013-10-10 Perseus Proteomics Inc. Conjugue d'anticorps anti-cdh3 anticorps (p-cadherine) et medicament
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CN110078827A (zh) 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
BR112014027166A2 (pt) 2012-05-01 2017-06-27 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP3925627A1 (fr) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Conjugués de médicaments et leurs utilisations
AU2013263002C1 (en) 2012-05-15 2018-05-31 Seagen Inc. Self-stabilizing linker conjugates
EP2852404B1 (fr) 2012-05-21 2017-07-26 Genentech, Inc. ANTICORPS ET IMMUNOCONJUGUÉS ANTI-Ly6E ET PROCÉDÉS D'UTILISATION
EP2867253B1 (fr) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Méthode de sélection et de production d'entités de ciblage personnalisées fortement sélectives et multi-spécifiques renfermant au moins deux entités de liaison différentes et leurs utilisations
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
RU2015106673A (ru) 2012-08-02 2016-09-20 Дженентек, Инк. Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты
US9463251B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
WO2014031498A1 (fr) 2012-08-18 2014-02-27 Academia Sinica Sondes perméables aux cellules pour l'identification et l'imagerie de sialidases
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
BR112015006505B1 (pt) 2012-09-26 2022-03-15 Immunogen, Inc Métodos de preparo de intermediários na síntese de maitansinoides
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
AU2013344778C1 (en) 2012-11-15 2024-06-27 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014089177A2 (fr) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
CN103333246B (zh) * 2012-12-21 2015-09-16 百奥泰生物科技(广州)有限公司 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
CN104650113A (zh) * 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
EP2961435B1 (fr) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
US9498532B2 (en) * 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP3299391B1 (fr) 2013-03-14 2019-12-04 Genentech, Inc. Anticorps et immunoconjugués anti-b7-h4
WO2014140300A1 (fr) 2013-03-15 2014-09-18 Innate Pharma Conjugaison d'anticorps en phase solide médiée par la tgase
EP3964237B1 (fr) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques
BR112015021134A2 (pt) * 2013-03-15 2017-10-10 Novartis Ag conjugados de fármaco e anticorpo
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2014194030A2 (fr) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
BR112015030514A2 (pt) * 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
EP3015116B1 (fr) 2013-06-24 2020-02-26 ABLBio Conjugué anticorps-médicament présentant une stabilité améliorée et son utilisation
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (fr) 2013-06-27 2014-12-31 Academia Sinica Conjugués de glycane et leur utilisation
AU2014286872B2 (en) 2013-07-05 2020-01-23 Formation Biologics Inc. EGFR antibody conjugates
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
RU2560699C2 (ru) * 2013-08-02 2015-08-20 федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
SG10201801779XA (en) 2013-09-05 2018-04-27 Jackson Lab Compositions for rna-chromatin interaction analysis and uses thereof
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
MX2016003248A (es) 2013-09-17 2016-06-07 Genentech Inc Metodos de uso de anticuerpos anti-lgr5.
NZ757964A (en) 2013-10-08 2022-07-01 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
KR102572149B1 (ko) 2013-10-11 2023-08-30 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
EP3057610B1 (fr) 2013-10-15 2021-09-22 Sorrento Therapeutics, Inc. Conjugués de médicament comportant une molécule de ciblage et deux médicaments différents
EP3456700A1 (fr) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
US9290578B2 (en) 2013-10-21 2016-03-22 Genentech, Inc. Anti-Ly6E antibodies and methods of use
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
JP2016538283A (ja) 2013-11-13 2016-12-08 ザイムワークス，インコーポレイテッド Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
CN105849568B (zh) 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
EP4570318A3 (fr) 2013-11-27 2025-10-15 Zymeworks BC Inc. Produits de recombinaison de liaison à l'antigène bispécifiques ciblant her2
WO2015089283A1 (fr) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Anticorps qui se lient à des anticorps activables et leurs procédés d'utilisation
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
PT3082878T (pt) 2013-12-19 2022-11-30 Seagen Inc Ligantes de carbamato de metileno para uso com conjugados de fármacos de marcação
US10214584B2 (en) 2014-01-15 2019-02-26 Order-Made Medical Research Inc. Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937731C (fr) 2014-01-27 2019-09-24 Pfizer Inc. Agents cytotoxiques bifonctionnels
RU2685728C2 (ru) 2014-01-29 2019-04-23 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения
US10464997B2 (en) 2014-02-11 2019-11-05 Seattle Genetics, Inc. Selective reduction of proteins
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
EP3129767B1 (fr) 2014-03-27 2021-09-01 Academia Sinica Composés de marquage réactifs et leurs utilisations
HRP20231139T1 (hr) 2014-05-06 2024-01-05 F. Hoffmann - La Roche Ag Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
DK3149045T3 (da) 2014-05-27 2023-03-06 Academia Sinica Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
WO2016004048A2 (fr) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Conjugués ciblés, particules et préparations associées
EP3164420A4 (fr) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Conjugués ciblés, particules et préparations associées
EP3160513B1 (fr) 2014-06-30 2020-02-12 Glykos Finland Oy Dérivé de saccharide d'une charge utile toxique et conjugués d'anticorps de celui-ci
WO2016008112A1 (fr) 2014-07-16 2016-01-21 Medshine Discovery Inc. Lieurs et application à des conjugués anticorps-médicament (acd) associée
PE20170903A1 (es) 2014-08-12 2017-07-12 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6
AU2015311951B2 (en) 2014-09-02 2021-04-08 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
PT3189056T (pt) 2014-09-03 2020-09-04 Immunogen Inc Derivados citotóxicos de benzodiazepina
EP3191500A4 (fr) 2014-09-08 2018-04-11 Academia Sinica Activation des cellules inkt humaines par des glycolipides
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
CA2961950A1 (fr) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation de cellules myeloides stimulatrices et non stimulatrices
WO2016059377A1 (fr) 2014-10-14 2016-04-21 Polytherics Limited Procédé pour la conjugaison d'un peptide ou d'une protéine avec un réactif comprenant un groupe partant comportant une partie de peg
PE20170912A1 (es) 2014-11-14 2017-07-12 Novartis Ag Conjugados de anticuerpo-farmaco
WO2016082044A1 (fr) 2014-11-27 2016-06-02 Zymeworks Inc. Procédés d'utilisation de constructions liant des antigènes bispécifiques ciblant her2
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
US10335495B2 (en) 2014-12-04 2019-07-02 Celgene Corporation Biomolecule conjugates
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
JP6871858B2 (ja) 2015-01-28 2021-05-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート
WO2016151432A1 (fr) 2015-03-20 2016-09-29 Pfizer Inc. Agents cytotoxiques bifonctionnels comprenant le pharmacophore cti
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
EP3286227A2 (fr) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Protéines multispécifiques de liaison à l'antigène
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
UA125496C2 (uk) 2015-06-08 2022-04-13 Дебіофарм Інтернаціонал, С.А. Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
CN106243127B (zh) * 2015-06-09 2021-01-26 凯惠科技发展(上海)有限公司 抗体药物偶联物、中间体、制备方法、药物组合物及应用
WO2016203432A1 (fr) 2015-06-17 2016-12-22 Novartis Ag Conjugués anticorps-médicament
MD3313845T2 (ro) 2015-06-29 2021-02-28 Immunogen Inc Conjugați cu anticorpi având cisteină modificată prin inginerie genetică
AU2016287304A1 (en) * 2015-06-30 2018-01-04 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3319936B1 (fr) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Lieux de pontage pour la conjugaison des molécules de liaison cellulaire
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
SMT202000004T1 (it) 2015-07-21 2020-03-13 Immunogen Inc Metodi di preparazione dei derivati citotossici di benzodiazepina
EP3331569A1 (fr) 2015-08-07 2018-06-13 Gamamabs Pharma Anticorps, conjugués anticorps-médicaments et procédés d'utilisation
AU2016316758B2 (en) 2015-08-28 2023-02-02 Debiopharm International, S.A. Antibodies and assays for detection of CD37
CN108348604B (zh) * 2015-09-08 2022-04-29 沃特世科技公司 用于分析抗体-药物缀合物的多维色谱方法
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
WO2017059551A1 (fr) 2015-10-08 2017-04-13 Zymeworks Inc. Constructions de polypeptides de liaison à l'antigène comprenant des chaînes légères kappa et lambda et leurs utilisations
HK1259311A1 (zh) 2015-10-28 2019-11-29 Tva (Abc), Llc Sstr靶向綴合物及其顆粒和製劑
US20170189548A1 (en) 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
EP3411074A4 (fr) 2016-02-04 2019-09-04 Suzhou M-conj Biotech Co., Ltd. Lieurs de conjugaison spécifique, immunoconjugués spécifiques de ceux-ci, procédés de fabrication et utilisations desdits conjugués de ceux-ci
WO2017147240A1 (fr) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Conjugués et particules ciblant hsp90 et leurs formulations
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
US9950070B2 (en) * 2016-08-16 2018-04-24 Korea University Research And Business Foundation HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CN109843334A (zh) 2016-10-18 2019-06-04 西雅图基因公司 烟酰胺腺嘌呤二核苷酸补救途径抑制剂的靶向递送
IL326918A (en) 2016-10-19 2026-05-01 Invenra Inc Antibody structures
WO2018083633A1 (fr) 2016-11-02 2018-05-11 Debiopharm International, S.A. Procédés d'amélioration d'une thérapie immunoconjuguée anti-cd37
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
TWI755450B (zh) 2016-11-23 2022-02-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
EP3548514A1 (fr) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer du sein positif à prlr
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
JP7681879B2 (ja) 2016-12-22 2025-05-23 ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
SI3558391T1 (sl) 2016-12-23 2022-06-30 Immunogen, Inc. Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN116785450A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018185618A1 (fr) 2017-04-03 2018-10-11 Novartis Ag Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
US20180311375A1 (en) * 2017-04-27 2018-11-01 Cadila Healthcare Limited Process of preparing antibody-drug conjugate
WO2018201087A1 (fr) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
RU2019142330A (ru) 2017-06-30 2021-07-30 Займворкс, Инк. Стабилизированные химерные fab
JP7241080B2 (ja) 2017-08-28 2023-03-16 アンジーエックス・インコーポレーテッド 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
WO2019057124A1 (fr) 2017-09-22 2019-03-28 Wuxi Biologics (Shanghai) Co., Ltd. Nouveaux complexes polypeptidiques cd3/cd19 bispécifiques
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
EP3732178A1 (fr) 2017-12-28 2020-11-04 ImmunoGen, Inc. Dérivés de benzodiazépine
WO2019150985A1 (fr) * 2018-01-31 2019-08-08 国立大学法人東京大学 Complexe anticorps-médicament et composition pharmaceutique le contenant
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CR20250325A (es) 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
CA3101790A1 (fr) 2018-05-30 2019-12-05 Debiopharm International, S.A. Regimes posologiques d'immunoconjugue anti-cd37
CA3102349A1 (fr) 2018-06-05 2019-12-12 King's College London Constructions de ciblage btnl3/8 pour l'administration de charges utiles au systeme gastro-intestinal
MX2020013466A (es) 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
CN112739340B (zh) 2018-07-23 2025-05-13 海德堡医药研究有限责任公司 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
BR112021001194A2 (pt) 2018-07-25 2021-04-27 Daiichi Sankyo Company, Limited métodos para produzir um conjugado anticorpo-fármaco e para produzir uma composição farmacêutica
BR112021004656A2 (pt) 2018-09-26 2021-06-01 Jiangsu Hengrui Medicine Co., Ltd. conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
CA3131391A1 (fr) 2019-02-27 2020-09-03 Angiex, Inc. Conjugues d'anticorps-medicament comprenant des anticorps anti-tm4sf1 et leurs methodes d'utilisation
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
WO2020187998A1 (fr) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Polythérapie à l'aide d'omomyc et d'un anticorps se liant à pd-1 ou ctla-4 pour le traitement du cancer
SG11202109986TA (en) 2019-03-20 2021-10-28 Univ California Claudin-6 antibodies and drug conjugates
WO2020191344A1 (fr) 2019-03-20 2020-09-24 The Regents Of The University Of California Anticorps de claudin-6 bispécifiques
EP3947395A1 (fr) 2019-03-29 2022-02-09 ImmunoGen, Inc. Dérivés de bis-benzodiazépine cytotoxiques et leurs conjugués avec des agents de liaison à une cellule pour inhiber la croissance cellulaire anormale ou pour traiter des maladies prolifératives
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
HUE065484T2 (hu) 2019-04-26 2024-05-28 Immunogen Inc Camptothecin-származékok
JP7604397B2 (ja) 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Ｐｓｍａコンジュゲートの調製方法
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
AU2020347715A1 (en) 2019-09-18 2022-04-07 Systimmune, Inc. Camptothecin derivative and conjugate thereof
WO2021060439A1 (fr) 2019-09-26 2021-04-01 日油株式会社 Polyéthylène glycol monodispersé hétérobifonctionnel ayant un lieur peptidique
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (fr) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugués de protéines de fusion du glp-1 et du fgf21
WO2021148003A1 (fr) 2020-01-22 2021-07-29 上海森辉医药有限公司 Conjugué de médicament à base de dérivé d'éribuline, son procédé de préparation et son application en médecine
BR112022017064A2 (pt) 2020-02-25 2022-11-16 Mediboston Inc Derivados da camptotecina e seus conjugados
CN111195353B (zh) * 2020-03-19 2023-06-23 烟台迈百瑞国际生物医药股份有限公司 一种美登素类抗体药物偶联物及其应用
WO2021190581A1 (fr) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un conjugué anticorps-médicament et son utilisation
JP7730836B2 (ja) 2020-03-25 2025-08-28 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体の調製方法
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
EP4319820A1 (fr) 2021-04-10 2024-02-14 Profoundbio Us Co. Agents de liaison à folr1, conjugués de ceux-ci et leurs procédés d'utilisation
JP7742892B2 (ja) 2021-04-23 2025-09-22 ジェンマブ エー／エス 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CA3238167A1 (fr) 2021-11-19 2023-05-25 Maria Leia Smith Agents de liaison de gpc3, leurs conjugues et leurs procedes d'utilisation
WO2023157989A1 (fr) 2022-02-17 2023-08-24 주식회사 노벨티노빌리티 Conjugué anticorps-médicament
AU2023229884A1 (en) 2022-03-09 2024-10-10 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
CN119234152A (zh) 2022-03-11 2024-12-31 阿斯利康(瑞典)有限公司 用于抗FRα抗体-药物缀合物疗法的评分方法
JP2025524986A (ja) 2022-07-27 2025-08-01 メディボストン リミテッド オーリスタチン誘導体およびそのコンジュゲート
AU2023370106A1 (en) 2022-10-25 2025-05-08 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
WO2024121632A1 (fr) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Utilisation d'un conjugué anticorps-médicament (adc) anti-cd117
IL322569A (en) 2023-02-09 2025-10-01 Beone Medicines I Gmbh Self-stabilizing bonding material bracelets
JP2026506049A (ja) 2023-02-16 2026-02-20 アストラゼネカ・アクチエボラーグ 治療用結合分子を用いた癌の治療のための併用療法
TW202438114A (zh) 2023-03-23 2024-10-01 瑞士商百濟神州瑞士有限責任公司 生物活性結合物、其製備方法及其用途
WO2024246657A1 (fr) * 2023-05-29 2024-12-05 Intas Pharmaceuticals Ltd. Procédé de conjugaison et de purification d'un conjugué anticorps-médicament
EP4473974A1 (fr) 2023-06-07 2024-12-11 Peptomyc, S.L. Polythérapie avec omomyc et des inhibiteurs de kras pour le traitement du cancer
WO2024251846A1 (fr) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Polythérapie avec des inhibiteurs de mek pour le traitement du cancer
KR20260020418A (ko) 2023-06-07 2026-02-11 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 Braf 저해제를 이용한 암 치료용 조합 요법
WO2024251240A1 (fr) 2023-06-09 2024-12-12 徕特康(苏州)生物制药有限公司 Conjugué anticorps-médicament bispécifique complémentaire anti-her2, son procédé de préparation et son utilisation
WO2025005240A1 (fr) 2023-06-30 2025-01-02 第一三共株式会社 Procédé de production de conjugué anticorps-médicament comprenant une étape de purification à l'aide d'un matériau de carbone actif
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025019790A1 (fr) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Traitement de patients atteints d'un cancer avec des thérapies par lymphocytes infiltrant les tumeurs en combinaison avec un adc ciblant trop-2
EP4509142A1 (fr) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 comme cible dans le traitement du cancer
WO2025072406A1 (fr) 2023-09-26 2025-04-03 Profoundbio Us Co. Agents de liaison ptk7, conjugués de ceux-ci et leurs procédés d'utilisation
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025094146A1 (fr) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasoconstricteurs pour réduire la toxicité oculaire de conjugués anticorps-maytansinoïde
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
TW202604965A (zh) 2024-04-24 2026-02-01 大陸商百奧賽圖(北京)醫藥科技股份有限公司 抗ｐｔｋ７／ｂ７ｈ３抗體及其用途
US20260048137A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026057740A1 (fr) 2024-09-12 2026-03-19 Astrazeneca Ab Traitement du cancer avec des molécules de liaison thérapeutiques

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
GB1603640A (en) 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS58167592A (ja) 1982-03-26 1983-10-03 Takeda Chem Ind Ltd 新規メイタンシノイド化合物
LU86212A1 (fr) 1985-12-16 1987-07-24 Omnichem Sa Nouveaux conjugues de la vinblastine et de ses derives,procede pour leur preparation et compositions pharmaceutiques les contenant
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
JPS6484959A (en) 1987-09-25 1989-03-30 Nec Corp System for connecting test line
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
FR2656555B1 (fr) * 1989-12-29 1994-10-28 Serimer Systeme mecanique de guidage automatique d'une ou plusieurs torches d'une unite de soudage a l'arc.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
CA2096417C (fr) 1991-08-22 2000-10-10 Sarah S. Bacus Methodes et compositions pour le traitement du cancer et pour predire les reactions a la therapie anticancereuse
CA2116774C (fr) 1991-09-19 2003-11-11 Paul J. Carter Expression dans e. coli de fragments d'anticorps ayant au moins une cysteine presente sous forme de thiol libre. utilisation pour la production d'anticorps f(ab') bifonctionnels
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
CA2076465C (fr) 1992-03-25 2002-11-26 Ravi V. J. Chari Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065
WO1993021319A1 (fr) 1992-04-08 1993-10-28 Cetus Oncology Corporation ANTICORPS HUMANISES SPECIFIES PAR C-erbB-2
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
JP2861631B2 (ja) 1992-05-06 1999-02-24 日本電気株式会社 Ｆｓｋ受信機
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
CA2120745A1 (fr) 1992-06-30 1994-01-06 Philip G. Kasprzyk Combinaison d'anticorps monoclonaux anti-erbb-2 et methode d'utilisation
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
RU2182598C2 (ru) 1994-11-21 2002-05-20 Новартис Аг Модифицированные ингибиторы протеиназы
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
US5614692A (en) 1995-06-30 1997-03-25 Tracor Aerospace, Inc. Shaped-charge device with progressive inward collapsing jet
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
EP0840770A4 (fr) 1996-05-23 2002-03-20 Ian Alexander Gilmour Procede d'extraction de proanthocyanidines de substances botaniques
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
JP2001502297A (ja) 1996-08-30 2001-02-20 イーライ・リリー・アンド・カンパニー 医薬用化合物
JPH1084959A (ja) * 1996-09-06 1998-04-07 Nobuyoshi Shimizu 細胞表面レセプターに対するモノクローナル抗体ならびにそのフラグメントの結合体ならびに複合体、それらの製法ならびに細胞への嵌入方法および使用方法
HU224196B1 (hu) * 1996-09-20 2005-06-28 Meiji Seika Kaisha Ltd. Cefditoren-pivoxil kristályos formája, és eljárás annak előállítására
EP0931147A1 (fr) 1996-10-18 1999-07-28 Genentech, Inc. ANTICORPS ANTI-ErbB2
EP1460083B1 (fr) 1996-11-06 2006-01-18 Sequenom, Inc. Procede d'analyse et dispositif
CA2274641A1 (fr) 1996-12-12 1998-06-18 David Richard Corbin Perfectionnement d'une composition pour emballage
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
CA2297070A1 (fr) 1997-08-01 1999-02-11 Morphosys Ag Nouvelle methode et nouveau phage d'identification d'une sequence d'acide nucleique
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
WO2000020579A1 (fr) 1998-10-02 2000-04-13 Mcmaster University Forme epissee de l'oncogene erbb-2/neu
AU770952B2 (en) 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
WO2000059473A1 (fr) 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Traitement du lymphome et composition a cet effet
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
JP2004506533A (ja) 1999-05-12 2004-03-04 アレイ　アクチボラゲット クリーニングユニットを備えた直接印刷装置
WO2000069460A1 (fr) 1999-05-14 2000-11-23 Genentech, Inc. Traitement avec des anticorps anti-erbb2
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
BRPI0012196B8 (pt) 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
JP4579471B2 (ja) 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
AU778863B2 (en) 1999-07-12 2004-12-23 Genentech Inc. Blocking immune response to a foreign antigen using an antagonist which binds to CD20
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
CA2385528C (fr) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
BE1012928A6 (nl) 1999-10-07 2001-06-05 Hoeberigs Jean Marie Mathieu Cilinderoven voor verwarming van frites met hete lucht.
BR0015224A (pt) 1999-10-29 2002-07-09 Genentech Inc Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US7365053B2 (en) * 2000-02-11 2008-04-29 Eli Lilly And Company Selective N-acylation of A82846 glygopeptides analogs
MXPA02007939A (es) 2000-02-24 2003-02-10 Genentech Inc Terapia con profarmacos activados por la caspasa.
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
AU2001283740A1 (en) 2000-08-17 2002-02-25 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
MXPA03001645A (es) 2000-08-24 2004-05-14 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2002057316A1 (fr) 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Nouvel anticorps monoclonal
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20080085283A1 (en) 2001-09-05 2008-04-10 Levinson Arthur D Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
KR20100061863A (ko) * 2001-09-05 2010-06-09 제넨테크, 인크. 이상 세포 증식을 포함하는 질환에 연관된 폴리펩티드 항원의 인식을 위한 방법 및 상기 질환 치료에 유용한 조성물
US20030109682A1 (en) * 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
ES2431929T3 (es) 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
WO2003057163A2 (fr) 2002-01-03 2003-07-17 Smithkline Beecham Corporation Preparation d'immunoconjugues
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
CA2491017A1 (fr) 2002-07-03 2004-01-15 Immunogen, Inc. Anticorps contre muc1 et muc16 non liberees et leurs utilisations
ES2361739T3 (es) * 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
AU2003259913A1 (en) 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7374762B2 (en) * 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR101672664B1 (ko) 2003-07-21 2016-11-04 이뮤노젠 아이엔씨 인간화된 항체 또는 그의 항원결정기 결합절편
US7754441B2 (en) 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP3991983B2 (ja) 2003-12-19 2007-10-17 日産自動車株式会社 車両の駆動制御装置
JP4658967B2 (ja) 2003-12-24 2011-03-23 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
EP1718667B1 (fr) 2004-02-23 2013-01-09 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
BRPI0613382A8 (pt) 2005-06-20 2018-01-02 Genentech Inc anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
US7195520B1 (en) 2006-07-18 2007-03-27 Chung-Chuan Huang Connector for antenna
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP2281006B1 (fr) * 2008-04-30 2017-08-02 Immunogen, Inc. Agents de réticulation et leurs utilisations
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
CN103476407A (zh) 2010-12-09 2013-12-25 霍夫曼-拉罗奇有限公司 用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症

Also Published As

Publication number Publication date
JP2012006928A (ja) 2012-01-12
AU2004282491B2 (en) 2010-12-23
US20110281856A1 (en) 2011-11-17
US20210261683A1 (en) 2021-08-26
CY2014002I2 (el) 2020-05-29
US20050169933A1 (en) 2005-08-04
EP2612682A3 (fr) 2013-09-25
CA3139478A1 (fr) 2005-04-28
US20140154804A1 (en) 2014-06-05
CN108578710A (zh) 2018-09-28
EA010508B1 (ru) 2008-10-30
BRPI0415448A8 (pt) 2019-08-13
SI1689846T1 (en) 2013-06-28
US20080171865A1 (en) 2008-07-17
US7989598B2 (en) 2011-08-02
CN103223174A (zh) 2013-07-31
EA200600752A1 (ru) 2007-08-31
CN107198778A (zh) 2017-09-26
JP2022068295A (ja) 2022-05-09
AU2010212291A1 (en) 2010-09-02
KR101573124B1 (ko) 2015-12-01
CA2542128C (fr) 2022-01-11
KR101476082B1 (ko) 2014-12-23
EP1689846B1 (fr) 2013-03-27
JP5718745B2 (ja) 2015-05-13
HUS1300075I1 (hu) 2014-02-28
US8685920B2 (en) 2014-04-01
BRPI0415448A (pt) 2006-12-05
KR20060130552A (ko) 2006-12-19
KR20140033003A (ko) 2014-03-17
ECSP066461A (es) 2007-05-30
US8563509B2 (en) 2013-10-22
IL173625A0 (en) 2006-07-05
JP5926759B2 (ja) 2016-05-25
US10844135B2 (en) 2020-11-24
CY2014002I1 (el) 2020-05-29
AU2010212291B2 (en) 2012-05-24
NO337458B1 (no) 2016-04-18
KR20130102649A (ko) 2013-09-17
US20080171856A1 (en) 2008-07-17
US20120226025A1 (en) 2012-09-06
WO2005037992A3 (fr) 2009-04-23
CA3237922A1 (fr) 2005-04-28
LU92336I9 (fr) 2019-01-16
JP2014177463A (ja) 2014-09-25
EP2596803A2 (fr) 2013-05-29
NO2016001I2 (no) 2016-01-26
PL1689846T3 (pl) 2013-07-31
EP1689846A2 (fr) 2006-08-16
US20170226220A1 (en) 2017-08-10
CA2542128A1 (fr) 2005-04-28
EP2596804A2 (fr) 2013-05-29
EP2596803A3 (fr) 2013-09-11
NO2016001I1 (no) 2016-01-26
KR20120034800A (ko) 2012-04-12
JP2020189854A (ja) 2020-11-26
US8088387B2 (en) 2012-01-03
JP2024059792A (ja) 2024-05-01
JP2016135786A (ja) 2016-07-28
IL246605A (en) 2017-08-31
US20080114153A1 (en) 2008-05-15
PT1689846E (pt) 2013-05-08
KR101343676B1 (ko) 2013-12-20
US20080145374A1 (en) 2008-06-19
DK1689846T3 (da) 2013-05-06
US8163888B2 (en) 2012-04-24
US8198417B2 (en) 2012-06-12
CN108578710B (zh) 2021-11-19
NZ545195A (en) 2010-07-30
NZ583844A (en) 2011-06-30
BE2013C075I2 (fr) 2023-12-18
EP2612682A2 (fr) 2013-07-10
EP1689846A4 (fr) 2010-08-04
IL214788A0 (en) 2011-11-30
HRP20130412T1 (en) 2013-06-30
IL173625A (en) 2016-07-31
FR13C0068I2 (fr) 2014-04-11
IL235253B (en) 2018-04-30
FR13C0068I1 (fr) 2014-01-17
JP2017200934A (ja) 2017-11-09
WO2005037992A2 (fr) 2005-04-28
JP2007520450A (ja) 2007-07-26
CY1113984T1 (el) 2016-07-27
EP2596804A3 (fr) 2013-09-18
NO20061772L (no) 2006-04-21
AU2004282491A1 (en) 2005-04-28
AU2010212291C1 (en) 2012-11-29
HK1244452A1 (zh) 2018-08-10
JP2019142864A (ja) 2019-08-29
ES2404304T3 (es) 2013-05-27
AU2004282491C1 (en) 2011-06-30
JP2019011363A (ja) 2019-01-24

Similar Documents

Publication Publication Date Title
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU93093I2 (fr) Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU93189I2 (fr) Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU91882I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LUC00127I1 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU92182I2 (fr) Dapagliflozine et ses sels pharmaceutiquement acceptables
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
LU93096I2 (fr) Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
LU92634I2 (fr) Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
AU2003264448A1 (en) Novel 6-substituted uracil derivative and therapeutic agent for allergic disease
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
IS7872A (is) Pýrrólópýrimidín afleiður
DE60324099D1 (de) Arzneistoffhaltiger tampon
DK1556385T3 (da) Heterocyclocarboxamid-derivater
AU2003304410A1 (en) Agents and methods for treatment of disease by oligosaccharide targeting agents
EP1570270A4 (fr) Bioconjugues therapeutiques